GLP2-T (Tirzepatide) is an FDA-approved dual GIP/GLP-1 receptor agonist. 2026 meta-analyses confirm superiority over semaglutide: -22.1% weight loss vs -17.1% at 12 months, with 95.2% achieving ≥10% loss. SURPASS trials show HbA1c reductions of 1.8-2.4%. Ongoing cardiovascular outcomes study (NCT07096063) compares long-term MACE endpoints vs semaglutide.
Research status
clinical investigational
Molecular weight
4813.45 g/mol
Molecular formula
C225H348N48O68
For research use only. This summary is a research-scientific overview compiled from peer-reviewed sources. It is not medical advice and is not intended for human or veterinary consumption.
Related products
Third-Party Tested by Verum Analytics
Dual GIP/GLP-1 receptor agonist — next-generation weight loss and metabolic-health peptide.
Third-Party Tested by Verum Analytics
Albert's Verdict
GLP2-T's intestinal trophic effects are highly localized — the receptor distribution in the gut mucosa is what makes it interesting as a standalone metabolic research target, separate from the GLP-1 pathway entirely.
View COA✓ In stock - Ships same day
Arrives as lyophilized (powder) form
Shipped freeze-dried for maximum stability and shelf life. See laboratory preparation guide for handling instructions.
Researchers also added
Research profile
A 39-residue synthetic peptide reported in the primary literature to engage both the GIP and GLP-1 receptors in in-vitro cAMP assays. For laboratory characterisation only.
Molecular formula
C225H348N48O68
Mechanism of action
Binding and functional-assay data for GLP2-T, from peer-reviewed in-vitro pharmacology publications. Values are receptor activity parameters — not clinical outcomes.
GIPR
GIP receptor
Full agonist (in vitro)
In-vitro cAMP assays report full agonism at the GIP receptor. The molecule is described as GIP-biased relative to native peptides.
Source: Coskun et al., Mol Metab 2018
GLP-1R
GLP-1 receptor
Partial agonist (in vitro)
In-vitro engagement of the GLP-1 receptor is reduced relative to native GLP-1; described in the primary literature as a partial agonist profile.
Source: Coskun et al., Mol Metab 2018
Receptor EC₅₀ values from in-vitro cAMP functional assays reported in peer-reviewed literature. In-vitro / preclinical characterisation only — no clinical or therapeutic claim is expressed or implied. Research use only.
Study framework
Study designs referencing this compound in the published literature. Descriptions cover framework only — phase, participant count, duration, and citation — not outcomes. Click a card to review the source directly.
Phase 3 SURPASS-2
Head-to-head vs GLP-1 mono-agonist · 40 weeks
Frías et al., NEJM 2021
SURMOUNT-1
N = 2,539 · 72-week weight-management RCT
Jastreboff et al., NEJM 2022
In-vitro pharmacology
Receptor binding · cAMP + β-arrestin assays
Coskun et al., Mol Metab 2018
Independent COA
≥99% purity · <0.05 EU/mL endotoxin · lot-specific
Freedom Diagnostic (accredited)
Compound comparison
Structural and in-vitro receptor-binding attributes of published incretin research compounds. Reference chemistry only — no comparative-effectiveness claim expressed or implied.
| Compound | GLP-1R | GIPR | GCGR | Sequence | MW | Half-life (lit.) | Reference |
|---|---|---|---|---|---|---|---|
GLP-3 (triple) triple | ✓ | ✓ | ✓ | 39 residues | 4731.32 g/mol | ~6 days (literature) | Coskun J Med Chem 2022 |
GLP-2 (dual) dual | ✓ | ✓ | — | 39 residues | 4813.5 g/mol | ~5 days (literature) | Coskun Mol Metab 2018 |
GLP-1 (single) single | ✓ | — | — | 31 residues | 4113.6 g/mol | ~7 days (literature) | Knudsen J Med Chem 2000 |
Reference chemistry only. Receptor-binding indications are qualitative (compound engages / does not engage the receptor in in-vitro assays as reported in the cited literature). No comparative-effectiveness claim is expressed or implied.
Cited sources
Independent published research indexed from PubMed and peer-reviewed journals — not BioInfinity claims.
Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)
2022 · N Engl J Med
View source
Tirzepatide versus Semaglutide once weekly in patients with type 2 diabetes (SURPASS-2)
2021 · N Engl J Med
View source
Tirzepatide for type 2 diabetes: SURPASS-1 trial
2021 · Lancet
View source
For research use only.
Not for human or veterinary use. All data on this page reflects chemistry attributes, in-vitro pharmacology, and study-framework metadata from published peer-reviewed literature. No statement describes or implies any therapeutic effect in humans. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.GLP2-T is a synthetic 39-amino-acid dual incretin receptor agonist. GLP2-T (Tirzepatide) is an FDA-approved dual GIP/GLP-1 receptor agonist. 2026 meta-analyses confirm superiority over semaglutide: -22.1% weight loss vs -17.1% at 12 months, with 95.2% achieving ≥10% loss. SURPASS trials show HbA1c reductions of 1.8-2.4%. Ongoing cardiovascular outcomes study (NCT07096063) compares long-term MACE endpoints vs semaglutide. It has a molecular formula C225H348N48O68, mass 4813.45 Da. Common synonyms in the literature include Tirzepatide, tirzepatide, and LY3298176.
Investigation of GLP2-T to date is clinical-investigational, with the majority of citations concentrated in animal models and in-vitro assays rather than randomized controlled human trials. Published work referencing GLP2-T spans SURPASS clinical trial program (Type 2 Diabetes): Seven Phase 3 trials comparing glp2-t (5, 10, 15 mg weekly) to placebo, glp1-s, insulin degludec, and insulin glargine. SURPASS-2 showed superior HbA1c reductions vs. glp1-s 1 mg (-2.0% to -2.3% vs. -1.9%). SURPASS-CVOT demonstrated non-inferiority for MACE with 10% risk reduction vs. dulaglutide, SURMOUNT clinical trial program (Obesity): SURMOUNT-1 (n=2,539) in non-diabetic adults showed 15 mg dose achieved 22.5% mean weight loss at 72 weeks vs. 2.4% placebo. SURMOUNT-2 in T2D patients showed 14.7% weight loss. SURMOUNT-3 and -4 evaluated weight maintenance and different populations, and Mechanism studies: Research demonstrates glp2-t enhances glucose-dependent insulin secretion more than selective GLP-1 agonists, likely through GIP-mediated potentiation. Studies show preferential fat mass reduction (fat:lean ratio ~8:1) compared to caloric restriction alone. Proposed mechanisms in the literature include GIPR full agonism: mimics native GIP, enhances post-meal insulin secretion, promotes lipid clearance and fat oxidation and GLP-1R biased partial agonism: favors cAMP over β-arrestin signaling, weaker receptor internalization vs native GLP-1. None of this material describes therapeutic outcomes in humans, and BioInfinity does not sell, market, or provide dosing guidance for GLP2-T outside laboratory research.
Lyophilized GLP2-T arrives as a fluffy off-white solid inside a sealed sterile vial. Because it ships as a lyophilized research compound (4813.45 Da), the powder is best stored between 2–8 °C prior to reconstitution and returned to −20 °C in aliquots for long-term storage post-reconstitution. Reconstitution is typically performed with bacteriostatic water (0.9 % benzyl alcohol preserved) rather than sterile water because the preservative extends solution stability once the vial has been punctured. Warming the reconstituted solution to room temperature before drawing helps redissolve any peptide that has settled against the vial wall. Avoid repeated freeze–thaw cycles: for peptides in this molecular-weight range (4813.45 Da), freeze–thaw stress is one of the most common causes of loss-of-purity between batches.
Every batch of GLP2-T ships with a batch-specific Certificate of Analysis produced by an ISO-accredited third-party analytical laboratory. Reversed-phase HPLC confirms the assay against the expected 4813.45 Da mass (C225H348N48O68); mass spectrometry validates the exact monoisotopic mass; endotoxin (LAL) testing confirms bacterial-contamination limits appropriate for laboratory research; and residual-solvent panels confirm the manufacturing pipeline. The lot number on the outer label matches the COA on the public /coa-library page — every purity claim is independently verifiable before you open the vial.
For the full mechanistic profile, published references, and constraint notes on GLP2-T, see the GLP2-T research page. All references cited on that page are peer-reviewed primary literature.
Research use only. GLP2-T is sold strictly for in-vitro and animal research. It is not a drug, food, supplement, or cosmetic and is not intended for human or veterinary consumption. No statements on this page describe or imply any therapeutic effect.
Commonly studied alongside in laboratory settings
Frequently asked questions about this compound for laboratory researchers.
Peer-reviewed literature relevant to GLP2-T research. Linked PubMed IDs open the original source.
6 verified buyers
I use to take ZEPBOUND. But then my insurance quit covering it. So I ordered the GLP2. I’ve been taking it for 2 months now. It helps curb my appetite a little bit, but not as much as I had hoped. I’m gonna try it one more month and if that doesn’t work, then I have to figure out something different to help with my weight loss.
Product performed in research that lined up with the disclosed purity and quality tests. Shipping was timely, and product arrived undamaged and properly protected. Bioinfinty Labs lives up to the hype!
Packaged great, quick shipping, easy customer service
Easy reconstitution, excellent quality and purity. Well packaged and good price.
Shipped quick, reconstituted easy great quality.
The product was easy to reconstitute and came with appropriate packaging that I found very useful for the integrity of the product. It was shipped quickly and no issues with packaging.
Reviews are submitted by verified buyers via per-order tokenized links. Reviews are evaluated for product-focused content; any review containing therapeutic claims (cured, treats, healed, etc.) may be edited or hidden to maintain compliance with FDA and platform guidelines.
Research Use Only: This product is intended for laboratory research purposes only. Not for human consumption.
